AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

Strong gains by the mining giants were not quite enough to keep the local bourse in the green, with every other sector losing ground. The benchmark S&P/ASX200 index on Friday finished down 9.1 points, ...

The tariff story isn’t over yet, with U.S. President announcing a new raft, but the global equity market reaction has been ...

Build, Monitor and Maintain Your Portfolio The Morningstar Investor Portfolio Manager is integrated with the Sharesight Investor Plan. We believe in focusing on the investor, before the investment - ...

With politicians unable to show fiscal restraint it was the bond vigilantes who would impose discipline. As Yardeni put it in ...

The merger injects new life into Platinum ( ASX: PTM ), helping to arrest the organic decline of its business by merging with ...

As Nvidia’s market cap has grown, it has become an increasingly large driver of overall market returns. Nvidia, which holds a ...

While pharmaceuticals are still exempt from US tariffs, President Donald Trump has threatened a potential 200% tariff on ...

Oftentimes, stock markets act like a pendulum and swing from overvalued to undervalued and back to overvalued again—and this ...

For comparison, WiseTech’s closest peers are estimated to have 95% customer retention rates. Although such scores are still ...

AI stocks have been more volatile than the overall technology sector, and “the uncertainty is legitimately higher,” Compton ...

Conventional wisdom tells retirees to seek safety with a conservative asset allocation in retirement. Is there a better way? After the recent market slump, it’s a good time to brush up on the ...